In MM, treatment with talquetamab, a bispecific mAb against the G protein-coupled receptor (GPRC5D), expressed on MM cells, enhanced the anti-MM activity of CD4 conventional T cells but also of T-reg cells. Here, CD4 is linked to Miyoshi myopathy.